Table 4 Prevalence of Pfcrt polymorphisms in paired pre-treatment and post-treatment samples in the artesunate-amodiaquine treatment arm, therapeutic efficacy monitoring, Mali, 2015 – 2016
Pre-treatment n, (%)* n = 26 | Post-treatment n, (%) n = 30 | p-value** | |
|---|---|---|---|
Pfcrt point mutations | |||
Pfcrt codon 72 | |||
C72 | 26 (100.0) | 30 (100.0) | NA |
Pfcrt codon 73 | |||
V73 | 26 (100.0) | 30 (100.0) | NA |
Pfcrt codon 74 | |||
M74 | 4 (15.4) | 16 (53.3) | 0.018 |
74M/I | 7 (26.9) | 2 (6.7) | |
74I | 15 (57.7) | 12 (40.0) | |
Pfcrt codon 75 | |||
N75 | 4 (15.4) | 16 (53.3) | 0.018 |
75N/E | 7 (26.9) | 2 (6.7) | |
75E | 15 (57.7) | 12 (40.0) | |
Pfcrt codon 76 | |||
K76 | 4 (15.4) | 16 (53.3) | 0.018 |
76K/T | 7 (26.9) | 2 (6.7) | |
76T | 15 (57.7) | 12 (40.0) | |
Pfcrt haplotypes† | |||
CVIET | 22 (84.6) | 14 (46.7) | 0.082 |
CVMNK | 11 (42.3) | 18 (60.0) | |